Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04731155
PHASE4

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Sponsor: Shanghai Tong Ren Hospital

View on ClinicalTrials.gov

Summary

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

Official title: Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2021-04-12

Completion Date

2025-10

Last Updated

2025-05-21

Healthy Volunteers

No

Interventions

DRUG

PCSK9 inhibitor (Alirocumab)plus standard medications

PCSK9 inhibitor(Alirocumab) was giving to subjects before PPCI and continued twice a month until 3 month after AMI

DRUG

standard medications

standard medications was giving to subjects according guidelines

Locations (2)

Tongren Hospital, Shanghai

Shanghai, Shanghai Municipality, China

Shanghai tenth people's hospital

Shanghai, China